Clinical trial
A Phase I Study of Autophagy Inhibition With Hydroxychloroquine and Oral Decitabine With Venetoclax After Hypomethylating Agent and Venetoclax Failure in Acute Myeloid Leukemia.
NCT07814339 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of Autophagy Inhibition With Hydroxychloroquine and Oral Decitabine With Venetoclax After Hypomethylating Agent and Venetoclax Failure in Acute Myeloid Leukemia.
- Lead sponsor
- Rutgers, The State University of New Jersey
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- September 30, 2026
- Completion date
- June 30, 2028
- Enrollment
- 18 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
acute myeloid leukemia